- Home
- BDTX vs DMAC Comparison
BDTX vs DMAC Comparison
Compare BDTX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- DMAC
- Stock Information
- Founded
- BDTX 2014
- DMAC 2000
- Country
- BDTX United States
- DMAC United States
- Employees
- BDTX N/A
- DMAC N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- DMAC Health Care
- Exchange
- BDTX Nasdaq
- DMAC Nasdaq
- Market Cap
- BDTX 181.4M
- DMAC 260.0M
- IPO Year
- BDTX 2020
- DMAC N/A
- Fundamental
- Price
- BDTX $2.93
- DMAC $5.06
- Analyst Decision
- BDTX Strong Buy
- DMAC Strong Buy
- Analyst Count
- BDTX 6
- DMAC 4
- Target Price
- BDTX $14.83
- DMAC $10.75
- AVG Volume (30 Days)
- BDTX 969.2K
- DMAC 353.4K
- Earning Date
- BDTX 08-05-2025
- DMAC 08-06-2025
- Dividend Yield
- BDTX N/A
- DMAC N/A
- EPS Growth
- BDTX N/A
- DMAC N/A
- EPS
- BDTX 0.09
- DMAC N/A
- Revenue
- BDTX $70,000,000.00
- DMAC N/A
- Revenue This Year
- BDTX N/A
- DMAC N/A
- Revenue Next Year
- BDTX N/A
- DMAC N/A
- P/E Ratio
- BDTX $33.20
- DMAC N/A
- Revenue Growth
- BDTX N/A
- DMAC N/A
- 52 Week Low
- BDTX $1.20
- DMAC $3.19
- 52 Week High
- BDTX $6.75
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- BDTX 56.77
- DMAC 66.99
- Support Level
- BDTX $3.02
- DMAC $4.81
- Resistance Level
- BDTX $3.28
- DMAC $5.25
- Average True Range (ATR)
- BDTX 0.19
- DMAC 0.45
- MACD
- BDTX -0.01
- DMAC 0.13
- Stochastic Oscillator
- BDTX 53.33
- DMAC 73.33
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.